Figure 6

Survival times and the proportion of animals surviving over time and serial mean changes in parameters in study 2. This figure shows the individual survival times for each of the animals assigned to hemodynamic support alone (HS; fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial blood pressure, respectively) and HS combined with raxibacumab administered at the start of (HS + mAbT0) or 6 h after (HS + mAbT6) after the start of lethal and edema toxin infusion in each of the three weekly experiments comprising Study 2 (A). This figure also shows the proportion of animals surviving over time in these three experiments combined (B). Finally, this figure compares the serial mean (±SEM) changes from baseline in fluid in (A), fluid out (B), net fluid (C), norepinephrine requirement (NE) (D), mean arterial blood pressure (MAP) (E), and shock index score (F), for animals receiving hemodynamic support alone (HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial blood pressure, respectively) versus combined with protective antigen directed monoclonal antibody administered at the start of (HS + mAbT0) or 6 h (HS + mAbT6) after the start of lethal and edema toxin challenge in Study-2. In panels C-H, the two raxibacumab groups are combined and designated HS+mAb. *p ≤ 0.05, **p < 0.0001.